Beyond The Numbers: 4 Analysts Discuss Longeveron Stock
Portfolio Pulse from Benzinga Insights
Longeveron (NASDAQ:LGVN) has received mixed analyst ratings over the past three months, with a decrease in the average 12-month price target from $11.75 to $9.0. Analysts have adjusted their ratings and price targets in response to market dynamics and company performance. Longeveron, a clinical-stage biotech company, has shown significant revenue growth but faces challenges with profitability and asset utilization.
August 27, 2024 | 3:00 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Longeveron has received mixed analyst ratings, with a decrease in the average price target from $11.75 to $9.0. Analysts have adjusted their ratings in response to market dynamics and company performance. Despite strong revenue growth, the company faces challenges with profitability and asset utilization.
The mixed analyst ratings and reduced price target suggest a neutral short-term impact on Longeveron's stock price. While the company has shown strong revenue growth, its profitability challenges and reduced price targets may offset positive sentiment.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100